Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?
Dec 22
French (CAC) Biotech Industry Analysis
UpdatedJan 30, 2023
DataAggregated Company Financials
Companies36
- 7D-1.7%
- 3M2.3%
- 1Y-41.0%
- YTD0.8%
Over the last 7 days, the Biotech industry has dropped 1.7%, driven by Valneva declining 6.6%. In contrast, MaaT Pharma has gained 9.2%. Overall the industry is down 41% in 12 months. Looking forward, earnings are forecast to grow by 21% annually.
Industry Valuation and Performance
Has the French Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 30 Jan 2023 | €3.7b | €1.0b | -€455,326,185.00 | 12.1x | -8.1x | 3.6x |
| Wed, 28 Dec 2022 | €3.4b | €1.0b | -€455,937,615.00 | 11.9x | -7.5x | 3.3x |
| Fri, 25 Nov 2022 | €3.5b | €1.0b | -€456,967,814.00 | 12.8x | -7.6x | 3.4x |
| Sun, 23 Oct 2022 | €3.7b | €913.5m | -€719,493,477.00 | 16.4x | -5.1x | 4x |
| Tue, 20 Sep 2022 | €3.9b | €961.7m | -€682,285,224.00 | 117.1x | -5.7x | 4x |
| Thu, 18 Aug 2022 | €4.7b | €931.3m | -€748,416,578.00 | 120.9x | -6.3x | 5.1x |
| Sat, 16 Jul 2022 | €4.3b | €984.5m | -€688,969,948.00 | 120.7x | -6.3x | 4.4x |
| Mon, 13 Jun 2022 | €4.5b | €990.4m | -€692,811,839.00 | 130.5x | -6.5x | 4.6x |
| Wed, 11 May 2022 | €4.3b | €1.0b | -€619,362,778.00 | 3.3x | -6.9x | 4.2x |
| Fri, 08 Apr 2022 | €5.1b | €1.2b | -€576,047,272.00 | 17.8x | -8.9x | 4.4x |
| Sun, 06 Mar 2022 | €4.7b | €950.3m | -€656,955,632.00 | 16.8x | -7.1x | 4.9x |
| Tue, 01 Feb 2022 | €5.3b | €932.4m | -€678,848,688.00 | 2.8x | -7.8x | 5.7x |
| Thu, 30 Dec 2021 | €7.1b | €928.4m | -€679,008,985.00 | 3.5x | -10.5x | 7.7x |
| Sat, 27 Nov 2021 | €7.3b | €925.7m | -€680,558,540.00 | 3.6x | -10.7x | 7.9x |
| Mon, 25 Oct 2021 | €7.0b | €927.7m | -€675,375,976.00 | 2.4x | -10.3x | 7.5x |
| Wed, 22 Sep 2021 | €6.8b | €893.6m | -€620,510,282.00 | 2.7x | -11x | 7.6x |
| Fri, 20 Aug 2021 | €6.4b | €899.6m | -€600,532,159.12 | 2.9x | -10.6x | 7.1x |
| Fri, 04 Jun 2021 | €6.7b | €882.0m | -€570,006,611.92 | 3x | -11.8x | 7.6x |
| Mon, 08 Mar 2021 | €7.2b | €911.8m | -€514,619,691.42 | 22.8x | -14x | 7.9x |
| Thu, 10 Dec 2020 | €5.8b | €737.3m | -€578,081,678.94 | 6.6x | -10x | 7.8x |
| Wed, 02 Sep 2020 | €4.2b | €624.3m | -€569,407,653.44 | 29.6x | -7.4x | 6.8x |
| Sat, 06 Jun 2020 | €4.2b | €608.4m | -€585,561,414.96 | 14.2x | -7.2x | 6.9x |
| Tue, 10 Mar 2020 | €4.2b | €548.6m | -€625,688,103.67 | 24.6x | -6.7x | 7.7x |
Price to Earnings Ratio
-7.1x
Current Industry PE
- Investors are pessimistic on the French Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 6.3x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 24% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the French Healthcare industry?
| FR Market | 1.41% | |
| Healthcare | -1.57% | |
| Biotech | -1.71% | |
| Biotech | -1.71% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| MAAT MaaT Pharma | €9.30 | 8.1% +€7.0m | -21.2% | PS85.5x | |
| ALERS Eurobio Scientific Société anonyme | €18.00 | 3.4% +€6.5m | -15.1% | PE4.2x | |
| ALONX Onxeo | €0.47 | 7.5% +€3.6m | 14.4% | PS15x | |
| IVA Inventiva | €5.80 | 1.4% +€3.4m | -46.2% | PS25.1x | |
| ALNFL NFL Biosciences | €3.06 | 17.7% +€2.4m | 61.9% | n/a |